Can PSMA PET help reduce unnecessary prostate biopsies without compromising cancer detection?
In this EMUC TV interview, our UROONCO PCa associate editor Dr. Jennifer Le Guévelou speaks with Prof. Veeru Kasivisvanathan about the results of the PRIMARY2 trial, a multicentre randomised study evaluating PSMA PET/CT in biopsy-naïve men with negative or equivocal MRI findings. Learn how PSMA PET may improve patient selection for biopsy, reduce unnecessary procedures, and contribute to a more personalised approach to prostate cancer diagnosis.